<DOC>
	<DOCNO>NCT02701985</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , two-treatment arm , parallel-group study design evaluate effect RO5459072 treatment disease activity symptoms Sjogren 's syndrome adult participant moderate severe primary Sjogren 's syndrome .</brief_summary>
	<brief_title>A Study Assess Efficacy RO5459072 Participants With Primary Sjogren 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>A diagnosis primary Sjogren 's syndrome accord revise AmericanEuropean Consensus Group ( AECG ) criteria European League Rheumatism ( EULAR ) Sjogren 's Syndrome Disease Activity Index ( ESSDAI ) score &gt; =5 EULAR Sjogren 's Syndrome Patient Reported Index ( ESSPRI ) score &gt; =5 Elevated serum titer antiSjogren'ssyndromerelated antigen A ( antiSSA ) and/or antiSjogren'ssyndromerelated antigen B ( antiSSB ) antibodies Negative pregnancy test ( woman ) Willing comply study procedure restriction , include measure prevent pregnancy restriction sperm donation A diagnosis secondary Sjogren 's syndrome Severe complications Sjogren 's syndrome Systemic immunosuppressant therapy , cyclophosphamide , Bcell deplete therapy within 6 month prior screen visit Corticosteroid therapy exceed 7.5 mg prednisone equivalent per day A history suggest reduce immune function condition predispose patient serious infection A history lymphoma , myeloma monoclonal gammopathy unknown significance ( MGUS ) , malignancy within past 5 year A diagnosis fibromyalgia significant depression Having concomitant disease condition could interfere conduct study , would pose unacceptable risk individual Participation investigational drug device study within 3 month prior screen Inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>